07:38 AM EST, 11/04/2025 (MT Newswires) -- Madrigal Pharmaceuticals ( MDGL ) reported a Q3 net loss Tuesday of $5.08 per diluted share, widening from a loss of $4.92 a year earlier.

Analysts polled by FactSet expected a loss of $2.29.

Net revenue for the quarter ended Sept. 30 was $287.3 million, up from $62.2 million a year earlier.

Analysts surveyed by FactSet expected $247.3 million.

Madrigal's stock was over 6% higher in recent Tuesday premarket activity.